Published in Clin Cancer Res on February 15, 2011
Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer. Breast Cancer Res Treat (2011) 1.30
The Akt signaling pathway: an emerging therapeutic target in malignant melanoma. Cancer Biol Ther (2011) 0.89
Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents. Onco Targets Ther (2011) 0.88
Metabotropic glutamate receptor 1 disrupts mammary acinar architecture and initiates malignant transformation of mammary epithelial cells. Breast Cancer Res Treat (2015) 0.80
Non-canonical Smads phosphorylation induced by the glutamate release inhibitor, riluzole, through GSK3 activation in melanoma. PLoS One (2012) 0.77
Disruption of GRM1-mediated signalling using riluzole results in DNA damage in melanoma cells. Pigment Cell Melanoma Res (2014) 0.77
Metabotropic glutamate receptors in cancer. Neuropharmacology (2016) 0.77
Effect of glutamate and riluzole on manganese-induced apoptotic cell signaling in neuronally differentiated mouse P19 Cells. Neurochem Int (2012) 0.76
Characterization of phosphodiesterase 2A in human malignant melanoma PMP cells. Oncol Rep (2013) 0.76
Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA (1998) 6.49
Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet (2003) 2.67
Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol (2004) 2.50
Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol (2004) 2.36
Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer (1978) 2.04
The pharmacology and mechanism of action of riluzole. Neurology (1996) 1.96
Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma. Cancer Res (2007) 1.82
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol (2003) 1.62
Stimulation of oncogenic metabotropic glutamate receptor 1 in melanoma cells activates ERK1/2 via PKCepsilon. Cell Signal (2005) 1.50
Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial. J Clin Oncol (2009) 1.41
Oncogenic activities of metabotropic glutamate receptor 1 (Grm1) in melanocyte transformation. Pigment Cell Melanoma Res (2008) 1.37
A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma. Clin Cancer Res (2009) 1.24
Radiation therapy of malignant melanoma: experience with high individual treatment doses. Cancer (1976) 1.16
Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer (2005) 1.13
Survival following whole brain radiation treatment for cerebral metastases: an audit of 474 patients. Radiother Oncol (2004) 1.07
Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol (2002) 1.05
The spectrum of in vitro radiosensitivity in four human melanoma cell lines is not accounted for by differential induction or rejoining of DNA double strand breaks. Int J Radiat Oncol Biol Phys (1995) 1.05
Pharmacologic approaches to the treatment of amyotrophic lateral sclerosis. BioDrugs (2005) 1.05
Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases. J Neurooncol (2006) 1.04
Temozolomide: a milestone in neuro-oncology and beyond? Expert Rev Anticancer Ther (2006) 1.02
Cloning of novel splice variants of mouse mGluR1. Brain Res Mol Brain Res (1999) 0.96
Development of heritable melanoma in transgenic mice. J Invest Dermatol (1998) 0.96
Radiotherapy for cutaneous malignant melanoma: rationale and indications. Oncology (Williston Park) (2004) 0.88
Riluzole for ALS: what is the evidence? Amyotroph Lateral Scler Other Motor Neuron Disord (2003) 0.87
Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). Cancer (2006) 0.87
Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck. Cancer (2004) 0.83
Melanoma metastatic to cervical lymph nodes: Can radiotherapy replace formal dissection after local excision of nodal disease? Head Neck (2005) 0.82
Radiosurgery plus whole-brain radiation therapy for brain metastases. JAMA (2006) 0.82
Radiation therapy for malignant melanoma. Surg Clin North Am (2003) 0.81
53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol (2010) 5.59
Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol (2006) 5.09
Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis. J Clin Oncol (2006) 4.66
MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell (2009) 4.47
Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys (2009) 3.91
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA (2013) 3.38
VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. Cancer Cell (2011) 3.23
Effectiveness of radiation therapy for older women with early breast cancer. J Natl Cancer Inst (2006) 2.69
Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet (2003) 2.67
Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol (2006) 2.49
Elf5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2. Nat Cell Biol (2012) 2.46
Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell (2007) 2.03
Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol (2006) 2.00
Factors that determine academic versus private practice career interest in radiation oncology residents in the United States: results of a nationwide survey. Int J Radiat Oncol Biol Phys (2013) 1.97
Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res (2008) 1.94
Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J Clin Oncol (2006) 1.85
Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma. Cancer Res (2007) 1.82
Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Int J Radiat Oncol Biol Phys (2010) 1.76
Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). J Am Coll Surg (2009) 1.76
Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res (2002) 1.69
GLI2-mediated melanoma invasion and metastasis. J Natl Cancer Inst (2010) 1.68
Positive sentinel nodes without axillary dissection: implications for the radiation oncologist. J Clin Oncol (2011) 1.60
Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women. Cancer (2003) 1.55
Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates. J Clin Oncol (2004) 1.54
Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells. J Clin Oncol (2011) 1.54
Stimulation of oncogenic metabotropic glutamate receptor 1 in melanoma cells activates ERK1/2 via PKCepsilon. Cell Signal (2005) 1.50
ACR Appropriateness Criteria® conservative surgery and radiation--stage I and II breast carcinoma: expert panel on radiation oncology: breast. Breast J (2011) 1.47
Effectiveness of radiation therapy in older women with ductal carcinoma in situ. J Natl Cancer Inst (2006) 1.44
The ubiquitin ligase Siah2 regulates tumorigenesis and metastasis by HIF-dependent and -independent pathways. Proc Natl Acad Sci U S A (2008) 1.42
Postoperative concurrent chemoradiotherapy with mitomycin in advanced squamous cell carcinoma of the head and neck: results from three prospective randomized trials. Cancer J (2006) 1.41
Hypofractionation in adjuvant breast radiotherapy. Breast (2010) 1.41
Oncogenic activities of metabotropic glutamate receptor 1 (Grm1) in melanocyte transformation. Pigment Cell Melanoma Res (2008) 1.37
Brachytherapy for accelerated partial-breast irradiation: a rapidly emerging technology in breast cancer care. J Clin Oncol (2010) 1.33
Coordinate autophagy and mTOR pathway inhibition enhances cell death in melanoma. PLoS One (2013) 1.32
Gender-related differences in outcome for melanoma patients. Ann Surg (2006) 1.32
Quantitative in situ measurement of estrogen receptor mRNA predicts response to tamoxifen. PLoS One (2012) 1.28
Characterization of folate uptake by choroid plexus epithelial cells in a rat primary culture model. J Neurochem (2007) 1.26
Rationalization and regionalization of treatment for ductal carcinoma in situ of the breast. Int J Radiat Oncol Biol Phys (2006) 1.25
Cloning and characterization of a novel gene, SHPRH, encoding a conserved putative protein with SNF2/helicase and PHD-finger domains from the 6q24 region. Genomics (2003) 1.25
A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma. Clin Cancer Res (2009) 1.24
The future of radiation oncology in the United States from 2010 to 2020: will supply keep pace with demand? J Clin Oncol (2010) 1.20
ACR appropriateness criteria on postmastectomy radiotherapy expert panel on radiation oncology-breast. Int J Radiat Oncol Biol Phys (2009) 1.20
ACR Appropriateness Criteria Breast Cancer Screening. J Am Coll Radiol (2013) 1.18
Differential expression of vascular endothelial growth factor-A isoforms at different stages of melanoma progression. J Am Coll Surg (2003) 1.15
Local-regional breast cancer recurrence: prognostic groups based on patterns of failure. Breast J (2002) 1.15
Lessons learned from the Sunbelt Melanoma Trial. J Surg Oncol (2004) 1.15
Association of nuclear localization of a long interspersed nuclear element-1 protein in breast tumors with poor prognostic outcomes. Genes Cancer (2010) 1.12
Quality measures, standards, and accreditation for breast centers in the United States. Int J Radiat Oncol Biol Phys (2010) 1.12
Clinicopathologic features and long-term outcome of patients with medullary breast carcinoma managed with breast-conserving therapy (BCT). Int J Radiat Oncol Biol Phys (2005) 1.11
Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat (2010) 1.10
Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients. J Clin Oncol (2004) 1.09
Significance of tumor biology on local control in breast cancer. Oncology (Williston Park) (2014) 1.08
Cyclin d1 is a valuable prognostic marker in oropharyngeal squamous cell carcinoma. Clin Cancer Res (2005) 1.08
LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-mTOR pathway. Oncotarget (2014) 1.08
Factors associated with false-negative sentinel lymph node biopsy in melanoma patients. Ann Surg Oncol (2009) 1.08
Progressive appearance of pigmentation in amelanotic melanoma lesions. Pigment Cell Res (2002) 1.08
The glutamate release inhibitor Riluzole decreases migration, invasion, and proliferation of melanoma cells. J Invest Dermatol (2010) 1.07
Identification and characterization of mouse Rab32 by mRNA and protein expression analysis. Biochim Biophys Acta (2003) 1.07
Ductal carcinoma in situ treated with breast-conserving surgery and radiotherapy: a comparison with ECOG study 5194. Cancer (2010) 1.06
Possession of ATM sequence variants as predictor for late normal tissue responses in breast cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.05
On the assay of brachytherapy sources. Med Phys (2007) 1.05
Repeat breast-conserving surgery for in-breast local breast carcinoma recurrence: the potential role of partial breast irradiation. Cancer (2004) 1.05
Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. Clin Cancer Res (2002) 1.04
A polymorphic variant in human MDM4 associates with accelerated age of onset of estrogen receptor negative breast cancer. Carcinogenesis (2009) 1.03
Characteristics and spectrum of BRCA1 and BRCA2 mutations in 3,922 Korean patients with breast and ovarian cancer. Breast Cancer Res Treat (2012) 1.02
Sun protection and exposure behaviors among Hispanic adults in the United States: differences according to acculturation and among Hispanic subgroups. BMC Public Health (2012) 1.02
Metabotropic glutamate receptors (mGlus) and cellular transformation. Neuropharmacology (2008) 1.02
Initial outcomes for patients treated on the American Society of Breast Surgeons MammoSite clinical trial for ductal carcinoma-in-situ of the breast. Ann Surg Oncol (2006) 1.02
Patterns of reduced nipple aspirate fluid production and ductal lavage cellularity in women at high risk for breast cancer. Breast Cancer Res (2005) 1.02
Riluzole prodrugs for melanoma and ALS: design, synthesis, and in vitro metabolic profiling. Bioorg Med Chem (2012) 1.02
Ipsilateral breast tumor recurrence after breast conservation therapy: outcomes of salvage mastectomy vs. salvage breast-conserving surgery and prognostic factors for salvage breast preservation. Int J Radiat Oncol Biol Phys (2005) 1.02
Psychosocial correlates of sun protection behaviors among U.S. Hispanic adults. J Behav Med (2014) 1.01
Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies. Clin Cancer Res (2011) 1.01
Bcl-2 expression predicts local relapse for early-stage breast cancer receiving conserving surgery and radiotherapy. Breast Cancer Res Treat (2008) 1.01
Radiation oncology, resident research, and the American Board of Radiology Holman Pathway. Int J Radiat Oncol Biol Phys (2005) 1.01
Conservative management of Paget disease of the breast with radiotherapy: 10- and 15-year results. Cancer (2003) 1.01
Identification of the DNA repair defects in a case of Dubowitz syndrome. PLoS One (2013) 1.00
Defining molecular phenotypes of human papillomavirus-associated oropharyngeal squamous cell carcinoma: validation of three-class hypothesis. Otolaryngol Head Neck Surg (2009) 0.99
The hormonal receptor status in breast cancer can be altered by neoadjuvant chemotherapy: a meta-analysis. Cancer Invest (2011) 0.99
Evaluation of acute locoregional toxicity in patients with breast cancer treated with adjuvant radiotherapy in combination with bevacizumab. Int J Radiat Oncol Biol Phys (2010) 0.99
Postmastectomy radiation and mortality in women with T1-2 node-positive breast cancer. J Clin Oncol (2005) 0.98
Exchange protein directly activated by cyclic AMP increases melanoma cell migration by a Ca2+-dependent mechanism. Cancer Res (2010) 0.98
Use of postmastectomy radiotherapy in older women. Int J Radiat Oncol Biol Phys (2007) 0.98
Linguistic acculturation and skin cancer-related behaviors among Hispanics in the southern and western United States. JAMA Dermatol (2013) 0.98
Curcumin downregulates the constitutive activity of NF-kappaB and induces apoptosis in novel mouse melanoma cells. Melanoma Res (2007) 0.97
G-protein-coupled receptors and melanoma. Pigment Cell Melanoma Res (2008) 0.97
53BP1 functions as a tumor suppressor in breast cancer via the inhibition of NF-κB through miR-146a. Carcinogenesis (2012) 0.96
Frequent alterations of Smad signaling in human head and neck squamous cell carcinomas: a tissue microarray analysis. Oncol Res (2003) 0.96
Outcomes in young women with breast cancer of triple-negative phenotype: the prognostic significance of CK19 expression. Int J Radiat Oncol Biol Phys (2007) 0.96
Identification of novel variants of metadherin in breast cancer. PLoS One (2011) 0.96
AKT2 is a downstream target of metabotropic glutamate receptor 1 (Grm1). Pigment Cell Melanoma Res (2009) 0.95
Detection of mutations in the mitogen-activated protein kinase pathway in human melanoma. Clin Cancer Res (2003) 0.95